Role of blue-light cystoscopy in the management of non-muscle invasive bladder cancer

被引:0
|
作者
Pignot, G. [1 ]
机构
[1] Univ Paris Sud, Hop Bicetre, Serv Urol, F-94270 Le Kremlin Bicetre, France
来源
PROGRES EN UROLOGIE | 2015年 / 25卷 / 10期
关键词
Non-muscle invasive bladder cancer; Cystoscopy; Diagnosis; Recurrence; Cost-effectiveness; Indications; GUIDED FLUORESCENCE CYSTOSCOPY; CARCINOMA IN-SITU; PHOTODYNAMIC DIAGNOSIS; COST-EFFECTIVENESS; FOLLOW-UP; COST/BENEFIT/THERAPEUTIC VALUE; TRANSURETHRAL RESECTION; FLEXIBLE CYSTOSCOPY; MUSCLE; RECURRENCE;
D O I
10.1016/j.purol.2015.05.003
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Blue-light cystoscopy aims to facilitate the detection of bladder tumors in order to optimize the completeness of resection. We performed a literature analysis using data from Medline and according to PRISMA guidelines. Several meta-analyses have confirmed the interest of the blue-light cystoscopy in terms of improved detection rate and disease-free survival compared to standard white-light cystoscopy. These benefits outweigh the initial costs related to the acquisition of specific equipment, allowing an improvement in quality-adjusted life-years and a reduction of costs over time. Indications vary according to guidelines and must take into account equipment and logistic constraints on each center. The objective of this article is to make a focus on the role and the interest of blue-light cystoscopy in the management of NMIBC in 2015. (C) 2015 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:607 / 615
页数:9
相关论文
共 50 条
  • [31] The role of hyperthermia as a treatment for non-muscle invasive bladder cancer
    Bahouth, Zaher
    Halachmi, Sarel
    Moskovitz, Boaz
    Nativ, Ofer
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (02) : 189 - 198
  • [32] Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden
    Rose, James B.
    Armstrong, Shannon
    Hermann, Gregers G.
    Kjellberg, Jakob
    Malmstrom, Per-Uno
    BJU INTERNATIONAL, 2016, 117 (6B) : E102 - E113
  • [33] Value of Fluorescence Cystoscopy in High Risk Non-muscle Invasive Bladder Cancer
    Roman Mayr
    Maximilian Burger
    Current Urology Reports, 2013, 14 : 90 - 93
  • [34] Cost-effectiveness of transurethral resection of the bladder with blue light in patients with non muscle invasive bladder cancer in France
    Roupret, M.
    Malavaud, B.
    Molinier, L.
    Leleu, H.
    Blachier, M.
    Marteau, F.
    PROGRES EN UROLOGIE, 2015, 25 (05): : 256 - 264
  • [35] Non-muscle invasive bladder cancer risk stratification
    Isharwal, Sumit
    Konety, Badrinath
    INDIAN JOURNAL OF UROLOGY, 2015, 31 (04) : 289 - 296
  • [36] Intravesical gemcitabine for non-muscle invasive bladder cancer
    Jones, Gabriel
    Cleves, Anne
    Wilt, Timothy J.
    Mason, Malcolm
    Kynaston, Howard G.
    Shelley, Mike
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (01):
  • [37] Blue versus white light for transurethral resection of non-muscle invasive bladder cancer
    Maisch, Philipp
    Koziarz, Alex
    Vajgrt, Jon
    Narayan, Vikram
    Ha Kim, Myung
    Dahm, Philipp
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (12):
  • [38] Prediction for recurrent non-muscle invasive bladder cancer
    Li, Keqiang
    Raveendran, Aravind
    Xie, Guoqing
    Zhang, Yu
    Wu, Haofan
    Huang, Zhenlin
    Jia, Zhankui
    Yang, Jinjian
    CANCER BIOMARKERS, 2023, 38 (03) : 275 - 285
  • [39] Emerging therapies in the management of high-risk non-muscle invasive bladder cancer (HRNMIBC)
    Werntz, Ryan P.
    Adamic, Brittany
    Steinberg, Gary D.
    WORLD JOURNAL OF UROLOGY, 2019, 37 (10) : 2031 - 2040
  • [40] Optimal intervals for follow-up cystoscopy in non-muscle invasive bladder cancer: a systematic review regarding oncological safety
    Dreyer, Thomas
    Ernst, Andreas
    Jensen, Jorgen Bjerggaard
    SCANDINAVIAN JOURNAL OF UROLOGY, 2022, 56 (01) : 39 - 46